PolyPid Ltd. entered into an exclusive License and Supply Agreement with Azurity Pharmaceuticals Ireland Ltd. on July 17, 2026, for the commercialization of D-PLEX 100 in the United States and Canada. The agreement includes a $15 million upfront payment and a $15 million near-term milestone payment upon FDA acceptance of the New Drug Application, which is expected in August 2026. PolyPid is eligible for up to $300 million in additional milestone payments and tiered royalties between mid-teen and mid-twenties percentages. PolyPid is a biopharmaceutical company that develops long-acting, controlled-release drugs for surgical care and metabolic diseases.
